Analysts Expect IJR Will Reach $131

The iShares Core S&P Small-Cap ETF (IJR) has an implied analyst target price of $130.96, indicating an 18.74% upside from its recent trading price of $110.29, derived from the weighted average of its underlying holdings' 12-month forward analyst targets. This potential upside is significantly driven by holdings such as Krystal Biotech Inc (KRYS), ePlus Inc (PLUS), and Cinemark Holdings Inc (CNK), which analysts project to have individual upsides of 55.33%, 43.07%, and 31.05% respectively. The analysis highlights potential opportunities within small-cap exposure while prompting investors to assess the validity and currency of these analyst targets.

Analysis

An analysis of the iShares Core S&P Small-Cap ETF (IJR) reveals a significant potential upside of 18.74%, based on a weighted average of its underlying holdings' 12-month forward analyst price targets. The implied target for the ETF is $130.96 per unit, compared to its recent trading price of $110.29. This optimistic outlook is heavily influenced by specific holdings with substantial projected gains, notably Krystal Biotech Inc (KRYS), ePlus Inc (PLUS), and Cinemark Holdings Inc (CNK). Analysts project a 55.33% upside for KRYS to a target of $209.60, a 43.07% upside for PLUS to $92.00, and a 31.05% upside for CNK to $33.67. While these figures suggest a potential valuation disconnect that favors investors, the information carries a cautious tone. The core of the analysis hinges on the validity of these analyst targets, which may be overly optimistic or may not reflect recent company-specific or industry-wide developments, necessitating further due diligence from investors before being acted upon.

Key Decisions for Investors

• Investors with a bullish outlook on the small-cap sector may consider the 18.74% implied upside in IJR a constructive data point, but should verify the thesis by examining the fundamental drivers of its key constituents.
• For those seeking alpha through individual stock selection, KRYS, PLUS, and CNK present as potential opportunities warranting deep-dive research to ascertain if their respective growth prospects justify the high analyst price targets.
• It is critical to assess the recency and justification of the analyst forecasts, as a significant gap between the stock price and target could be a precursor to target price downgrades if the optimism is unfounded.